Nothing Benign About It: BPH Drugs' Bids For Prostate Cancer Risk Reduction Voted Down By Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Reducing the risk of low-grade prostate cancers that may not affect a patient's health isn't worth the risk of increasing the numbers of high-grade tumors, ODAC says.
You may also be interested in...
Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim
GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.
Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim
GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.
GSK Loses Bid For Avodart Prostate Cancer Prevention Indication
FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.